AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03207204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Violet LED bleaching 2
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
Study NCT03006172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
Study NCT03207204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photochemical protocol 1
Description: Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
Study NCT03207204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photochemical protocol 2
Description: Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
Study NCT03207204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid technique 1
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
Study NCT03207204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid technique 2
Description: Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
Study NCT00744276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danazol
Description: danazol applied topically once per day for 4 treatment cycles
Study NCT00744276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo topically applied once daily for 4 treatment cycles
Study NCT03514589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tetracosactide
Description: Bioavailability of nasal synacthen compared to IV comparator
Study NCT02973828 — intervention group
Intervention type: PROCEDURE
Intervention: Imaging
Description: This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
Study NCT04633356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-portal pressure gradient measurement (PPGM)
Description: EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
Study NCT03009500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02376010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban
Study NCT02376010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
Study NCT03712293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBB Disruption with Chemotherapy Arm
Description: The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
Study NCT01619943 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: clinical follow up
Study NCT01619943 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02142439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Three times per week with strength training
Study NCT03006172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study NCT03006172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
Study NCT04205812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
Study NCT04245098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel syndrome surgery
Description: Biopsy
Study NCT03977155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-589
Description: oral tablets
Study NCT03977155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets
Study NCT00467493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT00467493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Study NCT01245023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adhesiolysis
Description: Laparoscopic adhesiolysis and Sprayshield
Study NCT01245023 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-surgery
Description: skin incisions without laparoscopy or related procedures
Study NCT00336063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT00336063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03009500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrol Injectable Product
Study NCT03009500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Sodium Chloride) solution
Study NCT03006172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
Study NCT03006172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
Study NCT03006172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
Study NCT03009500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
Study NCT03009500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
Study NCT01108120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intra-femoral thrombolysis group
Description: Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
Study NCT01108120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
Study NCT04798456 — intervention group
Intervention type: BEHAVIORAL
Intervention: Coma scales
Description: CRS-R and GOSE
Study NCT04798456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging, electrophysiology, body signals, and brain stimulation
Description: MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
Study NCT04798456 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: several questionnaires and an interview with the caregiver
Study NCT03594526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal support to become mother
Description: AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum.
Study NCT03594526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: usual care
Description: This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding.
Study NCT03278158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501, 8 mg/tablet
Description: Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
Study NCT00336063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00336063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT01891058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-shock vs shock only
Description: procainamide followed by electrocardioversion if necessary vs cardioversion only.
Study NCT01083238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: 120mg single oral dose
Study NCT01942447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Study NCT01942447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT04469725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 5 milligram per kilogram, every 2 weeks
Study NCT01309724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USCOM-guided fluid administration
Description: Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
Study NCT01439724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy- (DMC, São Paulo, Brazil)
Description: Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
Study NCT01439724 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (DMC, São Paulo, Brazil)
Description: The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
Study NCT03023709 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: quadrivalent, inactivated influenza virus vaccine, intramuscular
Study NCT03023709 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: quadrivalent, live, attenuated influenza vaccine, intranasal spray
Study NCT02136706 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Myocardial Perfusion imaging with 10 minute waiting period
Description: After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
Study NCT03292575 — intervention group
Intervention type: DRUG
Intervention: Anticoagulants
Study NCT04423510 — intervention group
Intervention type: PROCEDURE
Intervention: Crystallized phenol treatment
Study NCT01995643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Capsule
Description: GSE Capsule
Study NCT01995643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo Capsule
Study NCT01424709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel, CPT-11,Cisplatin
Description: Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
Study NCT01424709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/cisplatin
Description: gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
Study NCT02124486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
Study NCT02124486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietetic intervention
Description: Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
Study NCT00737438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Description: Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Study NCT00736814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given intravenously
Study NCT00736814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously
Study NCT00736814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given intravenously
Study NCT00736814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given intravenously
Study NCT00736814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given intravenously
Study NCT00736814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given intravenously
Study NCT00854542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry-based Culturally Sensitive Collaborative Treatment
Description: T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
Study NCT00854542 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telepsychiatry-based Culturally Sensitive Collaborative Treatment
Description: T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
Study NCT04112420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trans-esophageal echocardiography
Description: The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not.
Study NCT00929123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: manual therapy technique known to directly stress the median nerve